Tango Therapeutics TNGX Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss at other companies
Other financials
Where this comes from
Reported directly by Tango Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss.
The official record: Tango Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tango Therapeutics's debt securities, available-for-sale, continuous unrealized loss position, less than 12 months, accumulated loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tango Therapeutics's debt securities, available-for-sale, continuous unrealized loss position, less than 12 months, accumulated loss?
- Tango Therapeutics (TNGX) reported debt securities, available-for-sale, continuous unrealized loss position, less than 12 months, accumulated loss of $134K in Q1 2026.
- How has Tango Therapeutics's debt securities, available-for-sale, continuous unrealized loss position, less than 12 months, accumulated loss changed year-over-year?
- Tango Therapeutics's debt securities, available-for-sale, continuous unrealized loss position, less than 12 months, accumulated loss increased by 396.3% year-over-year, from $27K to $134K.
- What is the long-term trend for Tango Therapeutics's debt securities, available-for-sale, continuous unrealized loss position, less than 12 months, accumulated loss?
- Over 3 years (2021 to 2024), Tango Therapeutics's debt securities, available-for-sale, continuous unrealized loss position, less than 12 months, accumulated loss has grown at a -62.9% compound annual growth rate (CAGR), from $766K to $39K.